Tideglusib
As of the edition of 20 October 2026, Tideglusib is a small molecule: in active development; acts on GSK3B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 8, 0 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Inherited and neonatal; Eye; Mental health; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GSK3B | Glycogen synthase kinase-3 beta | P49841 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 2 | 4 | 3 | 1 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Noscira | Lead sponsor of trials | 2008 to now |
| AMO Pharma | Lead sponsor of trials |